Ferumoxytol

Generic Name: Ferumoxytol

Brand Names: Feraheme

Drug Type: Small Molecule

Chemical Formula: Fe_₃O_₄

CAS Number: 722492-56-0

Unique Ingredient Identifier: G6N3J05W84

Background: Ferumoxytol is an intravenously administered iron preparation indicated in the EU and the US for the treatment of iron deficiency anemia in adult patients with chronic kidney disease (CKD) .

It is comprised of superparamagnetic iron oxide nanoparticles which are coated by a semi-synthetic carbohydrate shell in an isotonic, neutral pH solution that may be administered at relatively high dose by rapid intravenous injection .

Indication: This drug is indicated for the treatment of iron deficiency anemia in adult patients who have experienced intolerance to oral iron or have experienced an unsatisfactory response to oral iron or

who have chronic kidney disease (CKD) .

Associated Conditions: Iron Deficiency Anemia (IDA)

Associated Therapies: -

Clinical Trials

Iron deficiency Anemia Therapeutics Market Size in the 7MM was around ...

DelveInsight's report on Iron Deficiency Anemia covers epidemiology, market trends in the US, EU4, UK, and Japan. Key trials include Dr. P. Noordzij's study on postoperative iron deficiency anemia treatment and RDC Clinical Pty Ltd's trial on IHAT. The US had 9.5 million prevalent cases in 2023, with females accounting for 65% of cases. Leading companies and therapies are highlighted, including MegaPro Biomedical's MPB-1514 and Pharmacosmos A/S's Ferric Derisomaltose. The report also discusses treatment strategies and market dynamics.

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy